# EDGAR Filing Document

**Accession Number:** 0001625297
**File Stem:** 0001625297-25-000069
**Filing Date:** 2025-11
**Character Count:** 6811
**Document Hash:** f82ee5f73ba3297ec9c112f13d19cf52
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001625297-25-000069.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001625297-25-000069

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251120

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INDIVIOR PLC
- **CENTRAL INDEX KEY:** 0001625297
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37835
- **FILM NUMBER:** 251503112

**BUSINESS ADDRESS:**
- **STREET 1:** 234 BATH ROAD
- **CITY:** SLOUGH, BERKSHIRE
- **STATE:** X0
- **ZIP:** SL1 4EE
- **BUSINESS PHONE:** 804-379-1090

**MAIL ADDRESS:**
- **STREET 1:** 234 BATH ROAD
- **CITY:** SLOUGH, BERKSHIRE
- **STATE:** X0
- **ZIP:** SL1 4EE

?xml version='1.0' encoding='ASCII'? indv-20251120

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 20, 2025

**INDIVIOR PLC**

(Exact name of registrant as specified in its charter)

England and Wales 001-37835 98-1204773 <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

10710 Midlothian Turnpike, Suite 125North Chesterfield, VA 23235 <br> (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: 804-379-1040

not applicable <br> (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Ordinary shares, $0.50 nominal value per share | INDV | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

**Item 1.02 Termination of a Material Agreement**

On November 20, 2025, Indivior, PLC (the "Registrant," or the "Company,") announced that it had satisfied its remaining obligations under that certain Resolution Agreement by and among Indivior Inc., Indivior PLC, the United States Attorney's Office for the Western District of Virginia, and the United States Department of Justice's Consumer Protection Branch made as of July 24, 2020 (the "Resolution Agreement"). As a result, the Resolution Agreement terminated on November 20, 2025.

**Item 7.01 Regulation FD Disclosure.**

On November 20, 2025, the Company issued a press release announcing the Company's payment of the remaining amounts owed to the DOJ. The press release is furnished as Exhibit 99.1 to this report and is incorporated herein.

**Item 9.01 Exhibits**

*(d) Exhibits.*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press release](ex991pressreleasedoj.htm) issued by Indivior PLC dated November 20, 2025. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | | **Indivior PLC** |
| &nbsp;&nbsp;Date: November 20, 2025 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: | /s/ Ryan Preblick |
|  |  | Name: Ryan Preblick |
|  |  | Title: Chief Financial Officer |

---

## Exhibit 99.1

**<u>Exhibit 99.1</u>**

![image_0.jpg](image_0.jpg)

**<u>Indivior Concludes Legacy U.S. Department of Justice Matter</u>**

**Richmond, VA, November 20, 2025** – Indivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ's receipt of the payment, the resolution agreement with the DOJ will be terminated. The payment was funded with Indivior's cash on hand.

"We are pleased to reach this important milestone that concludes the legacy DOJ matter," said Joe Ciaffoni, Chief Executive Officer. "It removes a significant liability and simplifies our capital structure. We are committed to conducting business with integrity, maintaining a comprehensive compliance program and acting in a responsible and transparent manner."

**<u>About Indivior</u>**

Indivior works to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a human crisis to a recognized and treated chronic disease. Building on its portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Visit <u>www.indivior.com</u> to learn more. Connect with Indivior on LinkedIn by visiting <u>www.linkedin.com/company/Indivior.</u>

**<u>For Further Information</u>**

Jason Thompson

VP, Investor Relations, Indivior PLC

+1 804-402-7123

<u>Jason.thompson@indivior.com</u>

Cassie France-Kelly

VP, Communications, Indivior PLC

+1 804-594-0836

<u>Indiviormediacontacts@indivior.com</u>

-ends-

<br>